吉利德科学Gilead Sciences (GILD) 2011年年度报告「NASDAQ」.pdf

1、Gilead Sciences Annual Report 2011Our FocusWe are an organization of more than 4,500 individuals working at 31 sites in 24 countries around the world.Together,we share one common focus,and that is advancing the discovery,development and delivery of new medications for people worldwide.Silvia,picture

2、d on the cover of this annual report,has been living with HIV since 1997.Her story is one of many that inspire us.Our FocusAdrian Ray,PhD,Principal Scientist,Drug Metabolism,Swami Swaminathan,PhD,Vice President of Structural Chemistry,and other dedicated researchers at Gilead are helping to advance

3、therapy for HIV/AIDS and other life-threatening conditions.1GILEAD 2011Derek Spencer is a nurse practitioner and a Baltimore native who recognized that providing comprehensive care and engaging the community in confronting HIV-related stigma could help address the epidemic in his city.In 2003,Derek

4、and his colleagues established the JACQUES Initiative,a multidisciplinary and holistic healthcare program that focuses on integrating outreach,screening and linkage to care,and treatment and retention.Gileads work in the lab and in the clinic has helped create more treatment options for patients and

5、 for healthcare professionals like Derek.Derek Spencer,MS,CNRPExecutive Director,JACQUES Initiative,Institute of Human Virology,University of Maryland,School of MedicineAbove:Hongmei Mo,MD,Director,Biology,Gilead Sciences2GILEAD 2011Forging PartnershipsCollaborations of all kinds across departments

6、at Gilead and with external partners enhance our ability to develop and deliver new products in multiple therapeutic areas.Whether in the lab or in the field,cross-functional teams work together to innovate in all aspects of our business.Gileads chemistry and biology teams work side by side,sharing